• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Apthera Engages Ferghana Partners for Private Equity Financings

Posted on: Wednesday, 11 April 2007, 15:00 CDT

Apthera is pleased to announce its engagement of Ferghana Partners Group (New York, Boston, London & Australia) to facilitate its Series C private equity investment as well as any future private equity rounds of investment. The Company has already completed its Series A round of investment and is in the process of completing a Series B bridging round. The Company intends to use the proceeds of its private equity financings to complete clinical development of NeuVaxTM for the treatment of early-stage breast cancer. Upcoming milestones include an End-of-Phase II meeting with the FDA, Special Protocol Assessment and the launch of phase III clinical studies. Apthera also plans to license additional peptide-based immunotherapies and initiate a Phase II clinical trial to evaluate NeuVax for the treatment of early-stage prostate cancer. In the near future, Apthera will enter into a corporate partnering process concerning the further development and commercialization of NeuVax on a global or regional basis.

The Ferghana Partners Group ("FPG") is an international provider of high level, independent corporate finance advice to firms in the Biotechnology, Pharmaceuticals, Diagnostics and Specialty Chemicals industries. FPG provides advice on corporate partnering/development and ownership/business portfolio topics, such as Mergers, Acquisitions, Joint Ventures and Divestitures to its clients, as well as creating and executing Financial Transactions. Its clients comprise both established Specialty Chemical, Pharmaceutical and Diagnostics companies as well as emergent Pharma and Biotechnology companies with a therapeutic or diagnostic focus.

Dr. Alton C. Morgan, Chairman, on behalf of the Board of Directors stated, "We are pleased to have the caliber of organization of Ferghana Partners to lead our next round(s) of investment. We look forward to working with the scientific and business teams led by Bill Kridel."

About Apthera

Apthera is focused on the development and commercialization of novel, peptide-based immunotherapies for the treatment of cancer. The Company's products have shown positive results in clinical trials targeting HER2-positive breast cancer. Apthera is privately held with headquarters in Scottsdale, Arizona. For more information about the Company visit www.apthera.com.

About NeuVax

NeuVax is completing Phase II clinical trials for the treatment of early stage breast cancer in patients expressing low (1+), moderate (2+) and high (3+) levels of HER2. To date, the results of the clinical study have demonstrated that NeuVax reduces the rate of cancer recurrence while showing minimal toxicity.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

Source: Business Wire

More News in this Category